You will recall from our Analyst Meeting last year that I said our priority was to consistently deliver strong adjusted EPS growth, and we clearly met that objective again in 2011. Before I cover our achievements for the full year, let's turn to the fourth quarter financials and I'll try to give you a sense of the playing field as we see it based on how our businesses closed out the year.
As you read in our press release, adjusted EPS for Q4 grew 23% to a record $1.18. Revenues in the fourth quarter increased 15% to a record $3.13 billion. We also expanded our adjusted operating margin by 100 basis points in the quarter to 18.9%.
We ended the year on a strong note and I'm especially pleased with our top line growth. We came in just above the high end of our expectations due to 3 reasons. First, our teams executed well against their plans. Second, we benefited from early traction on the additional share gain initiatives we put in place in the third quarter, which I'll highlight later in my remarks. And third, while the market conditions played out pretty much as we expected, we did see sequential improvement in the academic and government customer segment later in the quarter.
Let me take a few minutes to provide an overview of what we saw in our end markets in more detail. Let's start with academic and government. As you recall, we saw a significant slowdown in this end market in Q3. Uncertainty around the future of NIH budgets, as well as the budget crisis in many European countries was causing many of our customers to put their buying decisions on hold.In Q4, although conditions got sequentially better, the market was still relatively weak overall. Once the U.S. federal budget for 2012 was passed, with the small increase for NIH, we believe that our customers gain more confidence and that some pent-up demand kicked in late in the quarter, especially in spending for laboratory consumables.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV